Integrity Alliance LLC. Boosts Stake in Bristol Myers Squibb Company $BMY

Key Points

• Integrity Alliance LLC boosted its Bristol Myers Squibb stake by 314% in the fourth quarter, ending with 37,376 shares valued at about $2.0 million.
• Institutional interest in BMY remains strong, with major holders like Vanguard, State Street, and others increasing positions; overall, 76.41% of the stock is owned by hedge funds and institutional investors.
• Bristol Myers Squibb reported better-than-expected quarterly earnings and revenue, raised its FY 2026 EPS guidance, and continues to pay a quarterly dividend yielding about 4.4%.

Integrity Alliance LLC. raised its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 314.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,376 shares of the biopharmaceutical company's stock after buying an additional 28,348 shares during the period. Integrity Alliance LLC.'s holdings in Bristol Myers Squibb were worth $2,016,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Bristol Myers Squibb by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company's stock valued at $10,719,376,000 after buying an additional 2,743,759 shares during the last quarter. State Street Corp boosted its position in Bristol Myers Squibb by 2.0% in the 3rd quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company's stock valued at $4,356,445,000 after buying an additional 1,855,238 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Bristol Myers Squibb by 11.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 18,143,672 shares of the biopharmaceutical company's stock valued at $818,105,000 after buying an additional 1,873,618 shares during the last quarter. Pzena Investment Management LLC raised its stake in shares of Bristol Myers Squibb by 20.4% in the 4th quarter. Pzena Investment Management LLC now owns 17,943,503 shares of the biopharmaceutical company's stock valued at $967,873,000 after purchasing an additional 3,041,899 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in shares of Bristol Myers Squibb by 1.7% in the 4th quarter. Legal & General Group Plc now owns 17,366,032 shares of the biopharmaceutical company's stock valued at $936,724,000 after purchasing an additional 290,289 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the company's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.05% of the company's stock.

Bristol Myers Squibb Price Performance

BMY opened at $57.63 on Thursday. The firm has a market cap of $117.68 billion, a price-to-earnings ratio of 16.19, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The company's 50-day moving average price is $58.42 and its 200 day moving average price is $56.18. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same quarter in the prior year, the business earned $1.80 earnings per share. Bristol Myers Squibb's quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts expect that Bristol Myers Squibb Company will post 6.31 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were given a $0.63 dividend. The ex-dividend date was Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.4%. Bristol Myers Squibb's dividend payout ratio is 70.79%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Barclays assumed coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an "overweight" rating and a $75.00 target price on the stock. Wall Street Zen upgraded shares of Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research note on Sunday, April 19th. Piper Sandler restated an "overweight" rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Cantor Fitzgerald upped their target price on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a "neutral" rating in a research note on Wednesday, April 8th. Finally, Royal Bank Of Canada assumed coverage on shares of Bristol Myers Squibb in a research note on Tuesday, February 24th. They issued a "sector perform" rating and a $60.00 target price on the stock. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $61.31.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.